Meloxicam can provide modest short-term relief for sciatica, but the evidence is mixed. In one clinical trial, meloxicam reduced pain more than a placebo after seven days of use. However, a broader review of NSAIDs for radicular (nerve-related) back pain found no overall difference in pain intensity compared to placebo. How well meloxicam works for you depends largely on what’s driving your sciatica: inflammation around the nerve root, direct nerve damage, or both.
How Meloxicam Targets Sciatic Pain
Meloxicam is a selective COX-2 inhibitor, meaning it blocks a specific enzyme that ramps up after tissue injury or nerve compression. When a herniated disc or bone spur presses on a nerve root, the surrounding tissue produces inflammatory compounds called prostaglandins. These prostaglandins amplify pain signals, increase swelling, and sensitize the nerve. By blocking COX-2, meloxicam reduces the production of these compounds and can dial down both the inflammation and the pain that comes with it.
Research in animal models of nerve root compression shows meloxicam does more than just block prostaglandins at the surface level. It also suppresses a secondary inflammatory enzyme that breaks down cell membranes and feeds even more raw material into the inflammation cycle. This appears to reduce activation of immune cells in the spinal cord itself, which may explain why some people get meaningful relief while the drug is on board.
What the Clinical Evidence Shows
The clinical picture is less clear-cut than the lab science. A trial comparing meloxicam to placebo for sciatica found a statistically significant pain reduction after seven days, with a mean difference of about 6 points on a 100-point pain scale. That’s real but not dramatic. A separate trial using a similar NSAID found no difference from placebo after four weeks. When researchers pooled the data, the overall conclusion was that NSAIDs showed no meaningful advantage over placebo for radicular back pain, though the quality of evidence was rated low.
One trial directly compared meloxicam (at both 7.5 mg and 15 mg daily doses) against diclofenac, another common NSAID. Pain dropped significantly in all three groups over 14 days, but there was no difference between them. The amount of additional pain medication participants used was nearly identical across groups, suggesting meloxicam works about as well as other NSAIDs for this type of pain, not better or worse.
Why Sciatica Responds Differently Than Joint Pain
Sciatica is tricky because it usually involves two types of pain layered on top of each other. The first is inflammatory pain from swollen tissue pressing on the nerve root. Meloxicam handles this reasonably well, just as it does for arthritis. The second is neuropathic pain, which comes from the nerve itself being damaged or compressed. This produces burning, shooting, or electric-shock sensations that NSAIDs are generally considered ineffective against.
Most people with sciatica have some mix of both. If your pain is primarily an aching soreness in the lower back and buttock that worsens with certain positions, the inflammatory component may be dominant, and meloxicam is more likely to help. If your dominant symptoms are sharp, shooting pain down the leg, numbness, or tingling, the neuropathic component is probably larger, and meloxicam alone may fall short. This distinction matters because it shapes what additional treatments might be worth discussing with your provider.
How Quickly It Works
Meloxicam is slower to kick in than ibuprofen or naproxen. Blood levels peak about four to five hours after taking a tablet on an empty stomach, so don’t expect fast relief. The tradeoff is that it lasts a full 24 hours, so you only take it once a day. Steady-state levels, where the drug maintains a consistent presence in your system, are reached by day five. Many people notice the full effect only after several days of continuous use rather than from a single dose.
Combining With Nerve-Targeted Medications
Because meloxicam mainly addresses the inflammatory piece, doctors sometimes pair it with medications that target nerve pain directly. Gabapentin showed significant short-term pain relief for sciatica in one trial, reducing pain by roughly 27 points on a 100-point scale compared to placebo. That’s a substantially larger effect than any NSAID demonstrated in the same body of research. Combining an NSAID for inflammation with a nerve-targeted medication for the neuropathic component is a logical approach, though high-quality trials testing this specific combination are lacking.
Risks to Be Aware Of
Meloxicam carries an FDA boxed warning, the most serious type, for two categories of risk. The first is cardiovascular: all NSAIDs raise the risk of heart attack and stroke, and this risk can appear early in treatment and grows with longer use. The second is gastrointestinal: meloxicam can cause stomach bleeding, ulcers, or perforation without warning symptoms. About 1% of people taking NSAIDs for three to six months develop serious upper GI complications, rising to 2 to 4% after a year. People with a history of stomach ulcers or GI bleeding face more than ten times the risk.
Meloxicam should not be used by anyone with a history of allergic reactions to aspirin or other NSAIDs, particularly those with aspirin-sensitive asthma or nasal polyps. People with severe kidney disease should also avoid it, as NSAIDs can worsen kidney function. The general guidance from the FDA is to use the lowest effective dose for the shortest time possible.
Typical Dosing in Sciatica Trials
Clinical trials for sciatica used meloxicam at either 7.5 mg or 15 mg taken once daily, for periods ranging from 7 to 14 days. In the trial comparing meloxicam doses to diclofenac, both the 7.5 mg and 15 mg doses produced similar pain relief, and participants in all groups used comparable amounts of supplemental acetaminophen (roughly 750 mg per day on average). This suggests that for many people, the lower 7.5 mg dose may provide as much benefit as the higher one, with potentially fewer side effects.
Setting Realistic Expectations
Meloxicam is a reasonable option for managing sciatica in the short term, especially when inflammation is a significant contributor to your pain. But the honest summary of the research is that NSAIDs provide modest relief at best for radicular pain, and a systematic review in The BMJ concluded there is a “lack of conclusive and high quality evidence” to guide prescribing these drugs specifically for sciatica. It works about as well as other NSAIDs, not noticeably better, and it won’t address nerve damage on its own. For many people, it takes the edge off enough to stay mobile and participate in physical therapy, which remains one of the most consistently supported treatments for sciatica recovery.